Effect of Early Administration of Casirivimab and Imdevimab in Hospitalized Patients with COVID-19: A Post Hoc Analysis
Infection and Drug Resistance · 2026-06 · Volume 19 · 1-11
DOI: 10.2147/idr.s599451 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Drug Resistance, 2026-06. Verfasst von Eleftherios Mylonakis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Houston Methodist Hospital, Houston, TX, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Houston Methodist Hospital, Houston, TX, USA.
- Global Development, Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.
ORCID-Profile: Jiangnan Lyu
Zitieren
APA
Mylonakis, E., Sullivan, A., Somersan-Karakaya, S., You, X., Lyu, J., Shehadeh, F., & Geba, G. P. (2026). Effect of Early Administration of Casirivimab and Imdevimab in Hospitalized Patients with COVID-19: A Post Hoc Analysis. Infection and Drug Resistance, Volume 19, 1-11. https://doi.org/10.2147/idr.s599451
Vancouver
Mylonakis E, Sullivan A, Somersan-Karakaya S, You X, Lyu J, Shehadeh F, et al. Effect of Early Administration of Casirivimab and Imdevimab in Hospitalized Patients with COVID-19: A Post Hoc Analysis. Infection and Drug Resistance. 2026;Volume 19:1-11. doi:10.2147/idr.s599451
BibTeX
@article{Mylonakis2026,
author = {Mylonakis, Eleftherios and Sullivan, Amy and Somersan-Karakaya, Selin and You, Xiaojun and Lyu, Jiangnan and Shehadeh, Fadi and Geba, Gregory P},
title = {Effect of Early Administration of Casirivimab and Imdevimab in Hospitalized Patients with COVID-19: A Post Hoc Analysis},
journal = {Infection and Drug Resistance},
year = {2026},
volume = {Volume 19},
pages = {1--11},
doi = {10.2147/idr.s599451}
}
EUVIMED